These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 28403784)
21. Discovery of novel thiophene-3-carboxamide derivatives as potential VEGFR-2 inhibitors with anti-angiogenic properties. Li T; Wang J; Feng L; Zhou Q; Xie Q; Shen Y; Ji R; Liu X; Wang Y; Hu C Bioorg Chem; 2024 Jun; 147():107358. PubMed ID: 38626490 [TBL] [Abstract][Full Text] [Related]
22. Design, synthesis, biological evaluation and dynamics simulation of indazole derivatives with antiangiogenic and antiproliferative anticancer activity. Elsayed NMY; Serya RAT; Tolba MF; Ahmed M; Barakat K; Abou El Ella DA; Abouzid KAM Bioorg Chem; 2019 Feb; 82():340-359. PubMed ID: 30428414 [TBL] [Abstract][Full Text] [Related]
23. Molecular modelling and synthesis of quinazoline-based compounds as potential antiproliferative agents. Yassen AS; Elshihawy HE; Said MM; Abouzid KA Chem Pharm Bull (Tokyo); 2014; 62(5):454-66. PubMed ID: 24789927 [TBL] [Abstract][Full Text] [Related]
24. Synthesis and Biological Evaluation of Indole-2-carbohydrazide Derivatives as Anticancer Agents with Anti-angiogenic and Antiproliferative Activities. Zhang J; Liu T; Chen M; Liu F; Liu X; Zhang J; Lin J; Jin Y ChemMedChem; 2018 Jun; 13(12):1181-1192. PubMed ID: 29637713 [TBL] [Abstract][Full Text] [Related]
25. Novel multitarget inhibitors with antiangiogenic and immunomodulator properties. Conesa-Milián L; Falomir E; Murga J; Carda M; Marco JA Eur J Med Chem; 2019 May; 170():87-98. PubMed ID: 30878834 [TBL] [Abstract][Full Text] [Related]
26. Design and synthesis of novel pyridazinoquinazoline derivatives as potent VEGFR-2 inhibitors: In vitro and in vivo study. El-Gazzar MG; El-Hazek RM; Zaher NH; El-Ghazaly MA Bioorg Chem; 2019 Nov; 92():103251. PubMed ID: 31525526 [TBL] [Abstract][Full Text] [Related]
27. Flavonoids as a scaffold for development of novel anti-angiogenic agents: An experimental and computational enquiry. Gacche RN; Meshram RJ; Shegokar HD; Gond DS; Kamble SS; Dhabadge VN; Utage BG; Patil KK; More RA Arch Biochem Biophys; 2015 Jul; 577-578():35-48. PubMed ID: 25937258 [TBL] [Abstract][Full Text] [Related]
28. Synthesis, antitumor evaluation and docking study of novel 4-anilinoquinazoline derivatives as potential epidermal growth factor receptor (EGFR) inhibitors. Rao GW; Xu GJ; Wang J; Jiang XL; Li HB ChemMedChem; 2013 Jun; 8(6):928-33. PubMed ID: 23640754 [TBL] [Abstract][Full Text] [Related]
29. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466 [TBL] [Abstract][Full Text] [Related]
30. Design, synthesis and in vitro evaluation of 6-amide-2-aryl benzoxazole/benzimidazole derivatives against tumor cells by inhibiting VEGFR-2 kinase. Yuan X; Yang Q; Liu T; Li K; Liu Y; Zhu C; Zhang Z; Li L; Zhang C; Xie M; Lin J; Zhang J; Jin Y Eur J Med Chem; 2019 Oct; 179():147-165. PubMed ID: 31252306 [TBL] [Abstract][Full Text] [Related]
31. Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase. Peng FW; Wu TT; Ren ZW; Xue JY; Shi L Bioorg Med Chem Lett; 2015 Nov; 25(22):5137-41. PubMed ID: 26475519 [TBL] [Abstract][Full Text] [Related]
32. New 2,4-disubstituted-2-thiopyrimidines as VEGFR-2 inhibitors: Design, synthesis, and biological evaluation. Abdel-Mohsen HT; Girgis AS; Mahmoud AEE; Ali MM; El Diwani HI Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900089. PubMed ID: 31463965 [TBL] [Abstract][Full Text] [Related]
33. Discovery of new 4-alkoxyquinazoline-based derivatives as potent VEGFR2 inhibitors. Yin Y; Sha S; Wang YT; Wu X; Wang SF; Qiao F; Lv PC; Zhu HL Chem Biol Drug Des; 2015 Nov; 86(5):1323-9. PubMed ID: 26032487 [TBL] [Abstract][Full Text] [Related]
34. Effects of the tumor-vasculature-disrupting agent verubulin and two heteroaryl analogues on cancer cells, endothelial cells, and blood vessels. Mahal K; Resch M; Ficner R; Schobert R; Biersack B; Mueller T ChemMedChem; 2014 Apr; 9(4):847-54. PubMed ID: 24678059 [TBL] [Abstract][Full Text] [Related]
35. Design, One Pot Synthesis and Molecular Docking Studies of Substituted-1H-Pyrido[2,1-b] Quinazolines as Apoptosis-Inducing Anticancer Agents. Bathula R; Satla SR; Kyatham R; Gangarapu K Asian Pac J Cancer Prev; 2020 Feb; 21(2):411-421. PubMed ID: 32102519 [TBL] [Abstract][Full Text] [Related]
36. Novel chalcone derivatives as hypoxia-inducible factor (HIF)-1 inhibitor: synthesis, anti-invasive and anti-angiogenic properties. Wang L; Chen G; Lu X; Wang S; Han S; Li Y; Ping G; Jiang X; Li H; Yang J; Wu C Eur J Med Chem; 2015 Jan; 89():88-97. PubMed ID: 25462229 [TBL] [Abstract][Full Text] [Related]